BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)
Shots:
- The P-III (CheckMate-9ER) trial evaluates Opdivo + Cabometyx (n=323) vs sunitinib (n=328) in patients (N=651) with advanced or metastatic RCC. The 1EP of the study was PFS & 2EPs were OS & ORR
- At a median follow-up of 55.6mos., patients depicted a PFS of 16.4mos. vs 8.mos., OS of 46.5mos. vs 36mos., ORR of 55.7% vs 27.7%, CR of 13.6% vs 4.6% & DoR of 22mos. vs 15.2mos.
- Moreover, exploratory analysis showed an OS of 43.9mos. vs 29.3mos., mOS of 52.9mos. vs 58.9mos., PFS of 15.4mos. vs 7.1mos., ORR of 52.6% vs 23% CR of 12.9% vs 3.5% & DoR of 23.1mos. vs 13.8mos. In patients with favorable risk, PFS OS was 52.9mos. vs 58.9mos., PFS was 21.4mos. vs 12.8mos., ORR was 66.2% vs 44.4%, CR was 16.2% vs 8.3% & DoR was 18.7mos. vs 17.8mos.
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
